Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma

被引:97
作者
Dainty, Louis A.
Risinger, John I.
Morrison, Carl
Chandramouli, G. V. R.
Bidus, Michael A.
Zahn, Chris
Rose, G. Scott
Fowler, Jeff
Berchuck, Andrew
Maxwell, G. Larry
机构
[1] Walter Reed Army Med Ctr, Div Gynecol Oncol, Dept Obstet & Gynecol, Washington, DC 20307 USA
[2] Walter Reed Army Med Ctr, US Mil Canc Inst, Washington, DC 20307 USA
[3] NCI, Lab Biosyst & Canc, Canc Res Ctr, Bethesda, MD 20892 USA
[4] Mem Hlth Univ, Med Ctr, Dept Lab Oncol Res, Curtis & Elizabeth Anderson Canc Inst, Savannah, GA 31404 USA
[5] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA
[6] Ohio State Univ, Div Gynecol Oncol, James Canc Ctr, Columbus, OH 43210 USA
[7] Duke Univ, Med Ctr, Durham, NC 27110 USA
关键词
folate binding protein; papillary serous; gynecologic tumors;
D O I
10.1016/j.ygyno.2006.10.063
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. Folate receptor alpha (FOLR1) is a membrane bound receptor involved in the transport of folate as well as other regulatory cellular processes. The purpose of this study was to examine the expression of FOLR1 in uterine cancers and to identify changes in gene expression that are associated with overexpression of FOLR1. Experimental design. Fifty-eight frozen uterine cancer specimens were stained for FOLR1 using immunohistochemistry and results were correlated with transcript expression noted on quantitative PCR. Total RNA from 16 cases of uterine serous carcinoma (USC) was analyzed for gene expression using the Affymetrix HG-U133A and HG-U133B GeneChip set. USCs overexpressing FOLR1 were compared to cancers with an absence of FOLR1 using binary comparison and template matching of data was used to identify genes that correlate with FOLR1 expression. Selected targets from this analysis were evaluated by quantitative PCR as well as in an independent set of USC represented in quadruplicate on a tissue microarray (TMA). Results. Overexpression of FOLR1 was observed in 11/16 (69%) of USC and 0/10 normal endometrium cases using frozen tissue specimens. Binary comparison between FOLR1 positive and negative cases identified 121 genes altered by 2-fold at p < 0.01 of which 45 are well correlated with FOLR1 expression pattern. Using quantitative PCR, both mesothelin (MSLN) and PTGS1 (COX1) were significantly increased in FOLR1 overexpressing tumors (p = 0.014 and p = 0.006 respectively). TMA confirmed that overexpression of FOLR1 and MSLN respectively occurred in 23/48 (48%) and 17/54 (32%) of pure USC. Conclusion. Both FOLR1 and MSLN are cell surface targets that are co-expressed at high levels in USC and are appealing targets for biologic therapy. (c) 2007 Published by Elsevier Inc.
引用
收藏
页码:563 / 570
页数:8
相关论文
共 39 条
[1]  
AMATO RJ, 2004, 2004 ASCO ANN M P, V22, P4754
[2]   Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to α-folate receptor overexpression [J].
Bagnoli, M ;
Tomassetti, A ;
Figini, M ;
Flati, S ;
Dolo, V ;
Canevari, S ;
Miotti, S .
ONCOGENE, 2000, 19 (41) :4754-4763
[3]   A step further in understanding the biology of the folate receptor in ovarian carcinoma [J].
Bagnoli, M ;
Canevari, S ;
Figini, M ;
Mezzanzanica, D ;
Raspagliesi, F ;
Tomassetti, A ;
Miotti, S .
GYNECOLOGIC ONCOLOGY, 2003, 88 (01) :S140-S144
[4]   COMPARATIVE IMMUNOHISTOCHEMICAL STUDY OF 4 MONOCLONAL-ANTIBODIES DIRECTED AGAINST OVARIAN CARCINOMA-ASSOCIATED ANTIGENS [J].
BOERMAN, OC ;
VANNIEKERK, CC ;
MAKKINK, K ;
HANSELAAR, TGJM ;
KENEMANS, P ;
POELS, LG .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1991, 10 (01) :15-25
[5]   Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy [J].
Breidenbach, M ;
Rein, DT ;
Everts, M ;
Glasgow, JN ;
Wang, M ;
Passineau, MJ ;
Alvarez, RD ;
Korokhov, N ;
Curiel, DT .
GENE THERAPY, 2005, 12 (02) :187-193
[6]   DISTRIBUTION OF OV-TL-3 AND MOV18 IN NORMAL AND MALIGNANT OVARIAN TISSUE [J].
BUIST, MR ;
MOLTHOFF, CFM ;
KENEMANS, P ;
MEIJER, CJLM .
JOURNAL OF CLINICAL PATHOLOGY, 1995, 48 (07) :631-636
[7]  
CAMPBELL IG, 1991, CANCER RES, V51, P5329
[8]   REGRESSION OF ADVANCED OVARIAN-CARCINOMA BY INTRAPERITONEAL TREATMENT WITH AUTOLOGOUS T-LYMPHOCYTES RETARGETED BY A BISPECIFIC MONOCLONAL-ANTIBODY [J].
CANEVARI, S ;
STOTER, G ;
ARIENTI, F ;
BOLIS, G ;
COLNAGHI, MI ;
DIRE, EM ;
EGGERMONT, AMM ;
GOEY, SH ;
GRATAMA, JW ;
LAMERS, CHJ ;
NOOY, MA ;
PARMIANI, G ;
RASPAGLIESI, F ;
RAVAGNANI, F ;
SCARFONE, G ;
TRIMBOS, JB ;
WARNAAR, SO ;
BOLHUIS, RLH .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (19) :1463-1469
[9]   Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary [J].
Cao, DF ;
Ji, HX ;
Ronnett, BM .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2005, 24 (01) :67-72
[10]  
Corona G, 1998, INT J CANCER, V75, P125, DOI 10.1002/(SICI)1097-0215(19980105)75:1<125::AID-IJC19>3.0.CO